NCT07018622 2026-03-11
DAPA-ARMOR
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase 2 Recruiting
Clinical Trials
6 trialsNCT06130254 2025-10-14
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04515836 2025-05-06
Olaparib in Patients With HRD Malignant Mesothelioma
University of Chicago
Phase 2 Recruiting
NCT06686745 2025-01-07
Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06739395 2024-12-18
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT06525298 2024-09-19
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Eisbach Bio GmbH
Phase 1/2 Recruiting